Clinical trial

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-07-06

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2023-07-06Date precision: day

Registry last updated2026-08-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)unresolved

Pancreatic Adenocarcinomaunresolved

Non-small Cell Lung Cancer (NSCLC)unresolved

Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)unresolved

Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinomaunresolved

Triple Negative Breast Cancer (TNBC)unresolved

Interventions

SoCDRUG

Sponsors & collaborators

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.lead sponsor

Mapped research locations

BrusselsBelgium2 New YorkNew York, United States1 Los AngelesCalifornia, United States1 San AntonioTexas, United States1 LondonUnited Kingdom1 ColumbusOhio, United States1 ManchesterUnited Kingdom1 GlasgowUnited Kingdom1 Grand RapidsMichigan, United States1 LiègeBelgium1 AntwerpBelgium1 Newcastle upon TyneUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05985655 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.